Core Insights - FedEx reported strong fourth-quarter fiscal 2025 results, beating both earnings and revenue estimates, but provided a dismal outlook, leading to a more than 5% drop in shares after market close [1][3] Financial Performance - Earnings per share for FedEx were $6.07, surpassing the Zacks Consensus Estimate of $5.93 and improving from $5.41 a year ago [3] - Revenues increased by 0.5% year over year to $22.2 billion, exceeding the consensus estimate of $21.7 billion [3] Future Outlook - For the first quarter of fiscal 2026, FedEx expects revenues to be flat or increase by up to 2%, with adjusted earnings per share projected between $3.40 and $4.00 [4] - The Zacks Consensus Estimate for revenues indicates a growth of 0.21%, while the estimate for earnings per share is $4.05 [4] - FedEx did not provide earnings and revenue forecasts for fiscal 2026 due to uncertainties surrounding U.S. trade policies, particularly with China [5] Cost Management - FedEx achieved its $4 billion cost-cutting goal and aims to trim an additional $1 billion in the upcoming fiscal year [5] ETF Impact - The sluggish trading is expected to affect ETFs with high allocations to FedEx, including ProShares Supply Chain Logistics ETF, iShares U.S. Transportation ETF, First Trust Nasdaq Transportation ETF, and Pacer Industrials and Logistics ETF [2] ETF Details - ProShares Supply Chain Logistics ETF holds 40 stocks, with FedEx accounting for 4.6% of assets, and has an asset base of $0.9 million [6][7] - iShares U.S. Transportation ETF includes 44 securities, with FedEx making up 4.5% of assets and has $657.1 million in AUM [8][9] - First Trust Nasdaq Transportation ETF tracks 38 transportation securities, with FedEx accounting for 3.6% of the basket and has an asset base of $28.4 million [10][11] - Pacer Industrials and Logistics ETF tracks 109 stocks, with FedEx representing 3.1% of the holdings and has accumulated $1.6 million in assets [12][13]

Core Viewpoint - Idorsia Ltd. successfully held bondholder meetings to approve amendments to the terms of its convertible bonds, extending their maturity dates significantly [1][2][3]. Group 1: Bondholder Meetings - Two bondholder meetings were conducted for Idorsia's CHF 200 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [2]. - The amendments include extending the maturity date of the CB 2025 to July 17, 2034, and the CB 2028 to August 4, 2038 [2]. Group 2: Voting Outcomes - A significant majority of 89.5% of CB 2025 holders and 93.5% of CB 2028 holders voted in favor of the amendments, surpassing the required two-thirds majority [3]. - The amendments will become binding upon approval by the higher cantonal composition authority and are contingent on the completion of the repurchase offer for both bonds [3]. Group 3: Company Overview - Idorsia Ltd. aims to challenge medical paradigms and develop transformative medicines, positioning itself as a leading biopharmaceutical company [6]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drug discovery [7].

Company Acquisition - The Akkermansia Company (TAC) has been acquired by Danone, a leading global food and beverage company [1] Product Development - TAC's founding scientists discovered the biotic strain Akkermansia muciniphila MucT in 2004, demonstrating its ability to reinforce the gut barrier, reduce inflammation, and counteract metabolic disorders such as obesity, diabetes, and cardiovascular disease [2] - The company holds broad patents protecting the use of the Akkermansia species, including the pasteurized version MucT, which is its most bio-efficacious form [2] Market Expansion - TAC is expanding its business into key markets in Europe, North America, and Asia, aiming to accelerate global growth of the pasteurized Akkermansia muciniphila MucT strain [3] - The CEO of TAC expressed excitement about joining Danone, highlighting the resources that will facilitate faster brand development [3] Vision and Goals - TAC's Chief Technology Officer emphasized the goal of providing billions of consumers with improved metabolic health through Akkermansia [4] - The company aims to shift the focus of microbiome health from symptoms to root causes, positioning itself as a leader in next-generation probiotic and postbiotic supplements [5]

Core Insights - Holzer & Holzer, LLC is investigating Ichor Holdings, Ltd. for potential compliance issues with federal securities laws following disappointing Q1 2025 financial results [1] - Ichor's CEO indicated that the company's strategy did not yield the expected margin flow due to higher-than-forecasted external supply purchases [1] - The announcement of these results led to a decline in Ichor's stock price [1] Company Overview - Ichor Holdings, Ltd. trades on NASDAQ under the ticker ICHR [1] - The company reported its Q1 2025 financial results on May 5, 2025 [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Insights - Acuity (AYI) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 1.98% [1][2] - The company reported earnings of $3.73 per share for the most recent quarter, surpassing the expected $3.66, resulting in a surprise of 1.91% [2] - For the previous quarter, Acuity's earnings were $3.97 per share against an expectation of $3.89, yielding a surprise of 2.06% [2] Earnings Estimates and Predictions - Estimates for Acuity have been increasing, driven by its history of earnings surprises, and it currently has a positive Zacks Earnings ESP of +5.20% [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high likelihood of another earnings beat, with historical data showing that nearly 70% of stocks with this combination exceed consensus estimates [6][8] - The next earnings report for Acuity is anticipated to be released on June 26, 2025 [8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP can diminish predictive power but does not necessarily indicate an earnings miss [9] - It is crucial for investors to check a company's Earnings ESP prior to quarterly releases to enhance the chances of successful investment decisions [10]

Core Viewpoint - Levi Strauss (LEVI) has consistently beaten earnings estimates and is well-positioned for future earnings reports, particularly with a recent average surprise of 19.94% over the last two quarters [1][2]. Earnings Performance - For the last reported quarter, Levi Strauss achieved earnings of $0.38 per share, surpassing the Zacks Consensus Estimate of $0.28 per share, resulting in a surprise of 35.71% [2]. - In the previous quarter, the company was expected to post earnings of $0.48 per share but delivered $0.50 per share, yielding a surprise of 4.17% [2]. Earnings Estimates and Predictions - Recent estimates for Levi Strauss have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for Levi Strauss is +2.94%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [8]. Zacks Rank and Success Rate - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high probability of another earnings beat, with historical data indicating that stocks with this combination beat consensus estimates nearly 70% of the time [6][8]. Importance of Earnings ESP - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]. - A negative Earnings ESP reduces predictive power but does not necessarily indicate an earnings miss [9].

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ: GOCO) complied with federal securities laws. On May 1, 2025, the Department of Justice filed a complaint against GoHealth and others alleging that the Company, among other things, “knowingly entered into unlawful agreements to present false or fraudulent claims to the Government and performed acts in furtherance of this conspiracy.” Following this news, the price of ...

长江商报奔腾新闻记者潘瑞冬 浓缩果蔬汁龙头国投中鲁（600962）拟跨界电子信息产业和智慧城市等领域。 6月23日晚间，国投中鲁(600962.SH)公告称，公司控股股东国家开发投资集团有限公司(简称"国投集 团")拟筹划与公司有关的重大资产重组事项。 具体来看，国投中鲁拟向国投集团等相关方发行股份，购买中国电子工程设计院股份有限公司(简称"电 子院")控股权，同时定增募集配套资金。 值得一提的是，国投中鲁和电子院的控股股东均为国投集团。据悉，此次重组是国投集团优化资产布 局、提升证券化率的重要举措。 目前，该交易尚处于筹划阶段，具体交易金额还未披露。 资料显示，电子院以设计为龙头，聚焦电子信息产业和智慧城市等领域，拥有电子工程行业领先的核心 技术优势，以及拥有先进电子制造行业领先的工程建设、数字孪生技术、工业互联网整体解决方案能力 及智慧城市领域智能化建筑设计、建设、运维能力。 国投中鲁的经营范围主要是浓缩果蔬汁(浆)的生产和销售，主导产品为浓缩苹果汁，销售以出口为主。 公司通过全球化的生产和销售布局，在全球浓缩苹果汁行业处于龙头地位。 数据显示，2023年至2024年，国投中鲁盈利能力有所下滑，这两年公司 ...

资料显示，万豪钛金成立于2020年8月，主要从事钛及钛合金铸锭来料加工、成品铸锭国内外贸易、特 殊铸锭定制等业务。 长江商报奔腾新闻记者徐佳 募集资金及对外收购同步推进，宝钛股份（600456）(600456.SH)再谋产能扩张。 6月24日晚间，宝钛股份披露对外投资计划。公司拟以增资扩股方式取得陕西万豪钛金特材科技有限公 司(以下简称"万豪钛金")51%股权，增资价款2.87亿元。本次交易完成后，万豪钛金成为宝钛股份的控 股子公司，并拟更名为"陕西宝钛万豪钛业有限公司"。 2024年和2025年前三月，万豪钛金的营业收入分别为9328.8万元、3630.86万元，利润总额分别亏损 1133.18万元、281.44万元。 截至2025年3月末，万豪钛金总资产7.92亿元，总负债5.04亿元，净资产2.88亿元。 根据评估，本次交易中，万豪钛金股东全部权益账面价值为2.89亿元，股东全部权益评估价值为3.06亿 元，增值额为1738.06万元，增值率6.02%。 本次宝钛股份将对万豪钛金增资2.87亿元，其中5204.08万元计入万豪钛金注册资本，其余2.35亿元计入 万豪钛金资本公积。 长江商报奔腾新闻记者注 ...

Ford Motor is calling the majority of its salaried workforce back to the office four days a week, the automaker’s latest effort to boost employee and company performance.“Many of our employees have been in the office three or more days per week for some time now. We believe working together in person on a day-to-day basis will help accelerate Ford’s transformation into a higher growth, higher margin, less cyclical and more dynamic company,” a Ford spokesperson said in a statement in response to a Reuters qu ...